摘要
同功酶选择性血红素加氧酶(HO)抑制剂的开发有望提供强大的药理学工具来阐明HO系统的调节特性。已知HO具有细胞保护特性,在几种疾病状态中起作用;因此,它是一个诱人的治疗目标。历史上,金属卟啉已被用作竞争性HO抑制剂,基于它们与底物血红素的结构相似性。然而,血红素在几种其他蛋白质(例如细胞色素P450,一氧化氮合酶)中的重要作用导致非选择性是不幸的副作用。有报道称,azalanstat和其他非卟啉分子抑制HO导致了十多年前的多方面努力,开发出新型化合物作为HO的有效选择性抑制剂。结果是产生第一代基于非卟啉的非竞争性抑制剂,其具有对HO的选择性,包括对HO-1具有同工酶选择性的子集。使用X射线晶体学,已经阐明了几种HO-1与新型抑制剂的复合物的结构,并提供了关于抑制剂结合所需的显着特征的深刻信息。这包括非竞争性抑制的结构基础,抑制剂结合口袋的灵活性和适应性,以及多种潜在的相互作用亚位,所有这些都可以在未来的药物设计策略中得到利用。值得注意的是,HO-1抑制剂对于治疗高胆红素血症和某些类型的癌症特别感兴趣。基于该初步研究的关键特征已被其他人用于发现其他潜在的HO-1抑制剂。此外,研究已开始使用所选化合物并确定其在某些疾病模型中的作用。
关键词: 血红素,药物设计,X射线晶体学,唑类,血红素加氧酶-1,细胞色素P450。
Current Medicinal Chemistry
Title:Structural Insights into Azole-based Inhibitors of Heme Oxygenase-1: Development of Selective Compounds for Therapeutic Applications
Volume: 25 Issue: 42
关键词: 血红素,药物设计,X射线晶体学,唑类,血红素加氧酶-1,细胞色素P450。
摘要: The development of isozyme-selective heme oxygenase (HO) inhibitors promises powerful pharmacological tools to elucidate the regulatory characteristics of the HO system. It is already known that HO has cytoprotective properties with a role in several disease states; thus, it is an enticing therapeutic target. Historically, the metalloporphyrins have been used as competitive HO inhibitors based on their structural similarity to the substrate, heme. However, heme’s important role in several other proteins (e.g. cytochromes P450, nitric oxide synthase), results in non-selectivity being an unfortunate side effect. Reports that azalanstat and other non-porphyrin molecules inhibited HO led to a multi-faceted effort over a decade ago to develop novel compounds as potent, selective inhibitors of HO. The result was the creation of the first generation of non-porphyrin based, non-competitive inhibitors with selectivity for HO, including a subset with isozyme selectivity for HO-1. Using X-ray crystallography, the structures of several complexes of HO-1 with novel inhibitors have been elucidated and provided insightful information regarding the salient features required for inhibitor binding. This included the structural basis for non-competitive inhibition, flexibility and adaptability of the inhibitor binding pocket, and multiple, potential interaction subsites, all of which can be exploited in future drug-design strategies. Notably, HO-1 inhibitors are of particular interest for the treatment of hyperbilirubinemia and certain types of cancer. Key features based on this initial study have already been used by others to discover additional potential HO-1 inhibitors. Moreover, studies have begun to use selected compounds and determine their effects in some disease models.
Export Options
About this article
Cite this article as:
Structural Insights into Azole-based Inhibitors of Heme Oxygenase-1: Development of Selective Compounds for Therapeutic Applications, Current Medicinal Chemistry 2018; 25 (42) . https://dx.doi.org/10.2174/0929867325666180606082512
DOI https://dx.doi.org/10.2174/0929867325666180606082512 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements